BOSTON– Fortis Life Sciences, LLC (“Fortis”) has acquired Toronto-based International Point of Care, Inc. (“IPOC”). IPOC develops and manufactures key components used in diagnostics, including lyophilized reagents, membranes, recombinant proteins, and controls. With this acquisition, Fortis can provide its customers with a customizable, end-to-end solution to advance their immunodiagnostic and molecular diagnostic products. IPOC’s recently expanded 36,000 sq. ft. facility is Fortis’ third GMP and ISO 13485 compliant manufacturing site in North America.
“Diagnostics and life sciences companies want a partner that can custom-design and validate reagents for their applications; control quality and cost with vertically integrated in-house manufacturing; and help them get their products to market faster,” said Fred Pettijohn, Chief Business Officer of Fortis. “IPOC perfectly complements our existing capabilities, and we are pleased to introduce our expanded solution to the market.”
“We are excited to join Fortis and offer our customers a complete suite of high-quality materials and services,” said David Ray, CEO of IPOC. “Our combined expertise fully supports the diagnostic industry’s advances in ultra-high-sensitivity, point-of-care, and multiplexing applications, as well as in novel technologies such as quantitative lateral flow, isothermal amplification, and CRISPR-based diagnostics.”
